Ardena continues M&A strategy with CMO buy

By Flora Southey contact

- Last updated on GMT

(Image: Getty/mikdam)
(Image: Getty/mikdam)
CDMO Ardena has added drug product capabilities with the purchase of active pharmaceutical ingredient and excipient-focused Syntagon.

The acquisition enables the contract manufacturing and development organisation (CDMO) to handle larger batch sizes up to 100kg, adding a manufacturing facility in Södertälje, Sweden, and development and quality control (QC) laboratory in Riga, Latvia, to its site network.

Syntagon’s 30 employees and client portfolio will also be transferred to Ardena.

According to Ardena CEO Harry Christiaens, the firm’s Syntagon acquisition is in line with the its M&A strategy.

Ardena – which launched​ in September 2017 – is the product of a merger between Belgium-based Pharmavize, Dutch firm Crystallics, and Analytical Biochemical Laboratory (ABL) in The Netherlands.

And in March this year, the CDMO bought​ Dutch active pharmaceutical ingredient (API) maker ChemConnection.

Ardena is focused on building a “complementary service portfolio that spans the clinical supply chain from molecule to clinic,” ​Christiaens told us.

Services include chemical-pharmaceutical development and manufacturing services, analytical and bioanalytical support, and regulatory dossier development support, he added.

The acquisition marks the CDMO’s first outside of the Benelux region.

In Scandinavia, Ardena will be “well positioned to capitalise on the emerging biotech segment and broader pharmaceutical market,” ​the CEO said in a statement.

Related news

Related products

show more

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

SQ-USP-Brochure-Thumb-AP-CC

NEW…sugarcane derived USP Squalane from Aprinnova

APRINNOVA – A joint venture of AMYRIS and NIKKOL Group | 26-Feb-2018 | Product Brochure

To date, topical formulation chemists have been restricted to using Squalane derived from the harvesting of shark livers. Neossance Squalane USP, derived...

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers